Filters

See more specimen types...
See more states

Other countries

Results: 1 to 20 of 70

Tests names and labsConditionsGenes and analytesMethods

CentoCancer panel

Centogene AG - the Rare Disease Company
Germany
5231
  • C Sequence analysis of the entire coding region

FoundationOne®

Foundation Medicine, Inc.
United States
1315
  • D Deletion/duplication analysis
  • E Sequence analysis of select exons
  • C Sequence analysis of the entire coding region

CentoBreast (hereditary breast cancer) panel

Centogene AG - the Rare Disease Company
Germany
1013
  • C Sequence analysis of the entire coding region

Tempus xO assay

Tempus Labs, Inc.
United States
11714
  • R RNA analysis
  • C Sequence analysis of the entire coding region

Otogenetics Hereditary Cancers

Otogenetics
United States
3639
  • E Sequence analysis of select exons

Hereditary Cancer Panel Comprehensive

Molecular Genetics Laboratory London Health Sciences Centre
Canada
4030
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

FoundationOne® Heme

Foundation Medicine, Inc.
United States
2405
  • D Deletion/duplication analysis
  • R RNA analysis
  • E Sequence analysis of select exons
  • C Sequence analysis of the entire coding region

Breast cancer susceptibility to

Centogene AG - the Rare Disease Company
Germany
11
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Breast ovarian cancer panel

Centogene AG - the Rare Disease Company
Germany
1914
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Hereditary Cancer

Color Genomics, Inc.
United States
2429
  • C Sequence analysis of the entire coding region

NeoTYPE® Discovery Profile for Solid Tumors

NeoGenomics Laboratories NeoGenomics Laboratories, Inc.
United States
1315
  • I Immunohistochemistry
  • F Fluorescence in situ hybridization (FISH)
  • C Sequence analysis of the entire coding region

Tempus xT assay

Tempus Labs, Inc.
United States
2592
  • I Microsatellite instability testing (MSI)
  • R RNA analysis
  • C Sequence analysis of the entire coding region

Hereditary Ovarian Cancer Sequencing and Deletion/Duplication Panel

PreventionGenetics
United States
3521
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Providence Personalized Medicine Panel - Solid Tumor

Providence Regional Laboratories Providence Health and Services
United States
1308
  • C Sequence analysis of the entire coding region

VistaSeq Breast Cancer Panel

Molecular Diagnostic Laboratory LabCorp
United States
1619
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

VisaSeq Breast and GYN Cancer Panel

Molecular Diagnostic Laboratory LabCorp
United States
3225
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

qCancer Risk Expanded

Quantitative Genomic Medicine Laboratories, SL
Spain
145
  • C Sequence analysis of the entire coding region

qCancer Risk

Quantitative Genomic Medicine Laboratories, SL
Spain
130
  • C Sequence analysis of the entire coding region

CustomNext-Cancer

Ambry Genetics
United States
6867
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Vistaseq Hereditary Cancer Panel Without BRCA

Molecular Diagnostic Laboratory LabCorp
United States
1725
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Results: 1 to 20 of 70

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center